PD-L1 in Systemic Immunity: Unraveling Its Contribution to PD-1/PD-L1 Blockade Immunotherapy

被引：19

作者：

Bocanegra, Ana ^{[1
]}

Blanco, Ester ^{[1
]}

Fernandez-Hinojal, Gonzalo ^{[2
]}

Arasanz, Hugo ^{[1
]}

Chocarro, Luisa ^{[1
]}

Zuazo, Miren ^{[1
]}

Morente, Pilar ^{[1
]}

Vera, Ruth ^{[2
]}

Escors, David ^{[1
]}

Kochan, Grazyna ^{[1
]}

机构：

[1] IdISNA, Oncoimmunol Grp, Biomed Res Ctr Navarrabiomed UPNA, Irunlarrea 3, Pamplona 31008, Spain

[2] Complejo Hosp Navarra, IdISNA, Dept Oncol, Irunlarrea 3, Pamplona 31008, Spain

来源：

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES | 2020年 / 21卷 / 16期

关键词：

PD-L1; immunotherapy; immune; checkpoint inhibition; systemic myeloid subsets; liquid biopsy; biomarkers; CELL LUNG-CANCER; DEATH-LIGAND; CIRCULATING TUMOR-CELLS; NATURAL-KILLER-CELLS; SOLUBLE PD-L1; T-CELLS; DENDRITIC CELLS; OPEN-LABEL; NONCLASSICAL MONOCYTES; CLINICAL-SIGNIFICANCE;

D O I：

10.3390/ijms21165918

中图分类号：

Q5 [生物化学]; Q7 [分子生物学];

学科分类号：

071010 ; 081704 ;

摘要：

The use of monoclonal antibodies targeting PD-1/PD-L1 axis completely changed anticancer treatment strategies. However, despite the significant improvement in overall survival and progression-free survival of patients undergoing these immunotherapy treatments, the only clinically accepted biomarker with some prediction capabilities for the outcome of the treatment is PD-L1 expression in tumor biopsies. Nevertheless, even when having PD-L1-positive tumors, numerous patients do not respond to these treatments. Considering the high cost of these therapies and the risk of immune-related adverse events during therapy, it is necessary to identify additional biomarkers that would facilitate stratifying patients in potential responders and non-responders before the start of immunotherapies. Here, we review the utility of PD-L1 expression not only in tumor cells but in immune system cells and their influence on the antitumor activity of immune cell subsets.

引用

页码：1 / 17

页数：17

共 105 条

[1] Soluble programmed death-1 levels are associated with disease activity and treatment response in patients with autoimmune hepatitis [J].

Aarslev, Kristian ;

Dige, Anders ;

Greisen, Stinne R. ;

Kreutzfeldt, Martin ;

Jessen, Niels ;

Vilstrup, Hendrik ;

Deleuran, Bent ;

Gronbaek, Henning .

SCANDINAVIAN JOURNAL OF GASTROENTEROLOGY, 2017, 52 (01) :93-99

[2] Circulating Tumor Cell Clusters Are Oligoclonal Precursors of Breast Cancer Metastasis [J].

Aceto, Nicola ;

Bardia, Aditya ;

Miyamoto, David T. ;

Donaldson, Maria C. ;

Wittner, Ben S. ;

Spencer, Joel A. ;

Yu, Min ;

Pely, Adam ;

Engstrom, Amanda ;

Zhu, Huili ;

Brannigan, Brian W. ;

Kapur, Ravi ;

Stott, Shannon L. ;

Shioda, Toshi ;

Ramaswamy, Sridhar ;

Ting, David T. ;

Lin, Charles P. ;

Toner, Mehmet ;

Haber, Daniel A. ;

Maheswaran, Shyamala .

CELL, 2014, 158 (05) :1110-1122

[3] Circulating Tumor Cells Strategies for Capture, Analyses, and Propagation [J].

Agarwal, Ashutosh ;

Balic, Marija ;

El-Ashry, Dorraya ;

Cote, Richard J. .

CANCER JOURNAL, 2018, 24 (02) :70-77

[4] Plasma Levels of Soluble PD-L1 Correlate With Tumor Regression in Patients With Lung and Gastric Cancer Treated With Immune Checkpoint Inhibitors [J].

Ando, Kiyohiro ;

Hamada, Kazuyuki ;

Watanabe, Makoto ;

Ohkuma, Ryotaro ;

Shida, Midori ;

Onoue, Rie ;

Kubota, Yutaro ;

Matsui, Hiroto ;

Ishiguro, Tomoyuki ;

Hirasawa, Yuya ;

Ariizumi, Hirotsugu ;

Tsurutani, Junji ;

Yoshimura, Kiyoshi ;

Tsunoda, Takuya ;

Kobayashi, Shinichi ;

Wada, Satoshi .

ANTICANCER RESEARCH, 2019, 39 (09) :5195-5201

[5] Technologies for circulating tumor cell separation from whole blood [J].

Banko, Petra ;

Lee, Sun Young ;

Nagygyorgy, Viola ;

Zrinyi, Miklos ;

Chae, Chang Hoon ;

Cho, Dong Hyu ;

Telekes, Andras .

JOURNAL OF HEMATOLOGY & ONCOLOGY, 2019, 12 (1)

[6] Non-classical monocytes in tissue injury and cancer [J].

Bharat, Ankit ;

McQuattie-Pimentel, Alexandra C. ;

Budinger, G. R. Scott .

ONCOTARGET, 2017, 8 (63) :106171-106172

[7] PD-L1 expression on nonclassical monocytes reveals their origin and immunoregulatory function [J].

Bianchini, Mariaelvy ;

Duchene, Johan ;

Santovito, Donato ;

Schloss, Maximilian J. ;

Evrard, Maximilien ;

Winkels, Holger ;

Aslani, Maria ;

Mohanta, Sarajo K. ;

Horckmans, Michael ;

Blanchet, Xavier ;

Lacy, Michael ;

von Hundelshausen, Philipp ;

Atzler, Dorothee ;

Habenicht, Andreas ;

Gerdes, Norbert ;

Pelisek, Jaroslav ;

Ng, Lai Guan ;

Steffens, Sabine ;

Weber, Christian ;

Megens, Remco T. A. .

SCIENCE IMMUNOLOGY, 2019, 4 (36)

[8] PD-L1 Expression in Systemic Immune Cell Populations as a Potential Predictive Biomarker of Responses to PD-L1/PD-1 Blockade Therapy in Lung Cancer [J].

Bocanegra, Ana ;

Fernandez-Hinojal, Gonzalo ;

Zuazo-Ibarra, Miren ;

Arasanz, Hugo ;

Jesus Garcia-Granda, Maria ;

Hernandez, Carlos ;

Ibanez, Maria ;

Hernandez-Marin, Berta ;

Martinez-Aguillo, Maite ;

Jose Lecumberri, Maria ;

Fernandez de Lascoiti, Angela ;

Teijeira, Lucia ;

Morilla, Idoia ;

Vera, Ruth ;

Escors, David ;

Kochan, Grazyna .

INTERNATIONAL JOURNAL OF MOLECULAR SCIENCES, 2019, 20 (07)

[9] Nivolumab versus Docetaxel in Advanced Nonsquamous Non-Small-Cell Lung Cancer [J].

Borghaei, H. ;

Paz-Ares, L. ;

Horn, L. ;

Spigel, D. R. ;

Steins, M. ;

Ready, N. E. ;

Chow, L. Q. ;

Vokes, E. E. ;

Felip, E. ;

Holgado, E. ;

Barlesi, F. ;

Kohlhaeufl, M. ;

Arrieta, O. ;

Burgio, M. A. ;

Fayette, J. ;

Lena, H. ;

Poddubskaya, E. ;

Gerber, D. E. ;

Gettinger, S. N. ;

Rudin, C. M. ;

Rizvi, N. ;

Crino, L. ;

Blumenschein, G. R. ;

Antonia, S. J. ;

Dorange, C. ;

Harbison, C. T. ;

Finckenstein, F. Graf ;

Brahmer, J. R. .

NEW ENGLAND JOURNAL OF MEDICINE, 2015, 373 (17) :1627-1639

[10] Neutrophil-to-lymphocyte ratio as prognostic indicator in gastrointestinal cancers: a systematic review and meta-analysis [J].

Bowen, Randy C. ;

Little, Nancy Ann B. ;

Harmer, Joshua R. ;

Ma, Junjie ;

Mirabelli, Luke G. ;

Roller, Kyle D. ;

Breivik, Andrew Mackay ;

Signor, Emily ;

Miller, Alec B. ;

Khong, Hung T. .

ONCOTARGET, 2017, 8 (19) :32171-32189

← 1 2 3 4 5 6 7 8 9 10 →